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Abstract
Background: Dual bronchodilation combining a long-acting β2-agonist (LABA) and a long-acting muscarinic
antagonist (LAMA) is the preferred choice of treatment recommended by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) 2017 guidelines for the management of patients with moderate-to-severe chronic
obstructive pulmonary disease (COPD). The once-daily (q.d.) fixed-dose combination (FDC) of LABA, indacaterol
110 μg and LAMA, glycopyrronium 50 μg (IND/GLY 110/50 μg q.d.) demonstrated superior improvements in lung
function, dyspnoea and overall health status and better tolerability against LABA or LAMA monotherapies and
combination of LABA and inhaled corticosteroid (ICS) in more than 11,000 patients with moderate-to-severe COPD
in several randomised controlled clinical trials.
Methods: The CRYSTAL study was the first, 12-week, randomised, open-label trial that evaluated the efficacy and
safety of a direct switch from previous treatments to IND/GLY 110/50 μg q.d. on lung function and dyspnoea in
patients with moderate COPD and a history of up to one exacerbation in the previous year. Patients were divided
into 2 groups according to their background therapy and symptom scores and were randomised (3:1) to IND/GLY
or to continue with their previous treatments.
Results: The study included 4389 randomised patients, of whom 2160 were in groups switched to IND/GLY
(intention-to-treat population). The effect of IND/GLY was superior to LABA + ICS on trough forced expiratory
volume in 1 s (FEV1; treatment difference, Δ = +71 mL) and transition dyspnoea index (TDI; [Δ = 1.09 units]), and to
LABA or LAMA on trough FEV1 (Δ = +101 mL) and a TDI (Δ = 1.26 units). Improvements in health status and lower
rescue medication use were also observed with IND/GLY. The safety profile of the study medication was similar to
that observed in previous studies.
Conclusions: IND/GLY demonstrated superior improvements in lung function and dyspnoea after direct switch
from previous treatments.
Trial registration: ClinicalTrials.gov number: NCT01985334.
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Background
Maintenance inhaled treatment of chronic obstructive
pulmonary disease (COPD) is based on long-acting
β2-agonist (LABA) and/or long-acting muscarinic an-
tagonists (LAMA) and LABA/inhaled corticosteroid
(ICS) [1]. Despite treatment, most of the patients re-
main symptomatic, requiring a change in therapy [2].
A once-daily (q.d.) combination of indacaterol and glyco-
pyrronium (IND/GLY) was effective and well tolerated in
patients with moderate-to-severe COPD in several phase
III trials [3, 4]. Such pivotal trials are usually performed in
selected patients and hospital settings [5]. Patients with
COPD treated in primary care settings often differ from
those included in large randomised controlled trials (RCTs)
[6]. Moreover, in RCTs, prior to randomisation, patients
typically go through a washout period, in contrast to
clinical practice where treatment changes occur without
any washout period [5]. The effectiveness of a treatment in
clinical practice can be evaluated more appropriately in a
direct switch study in primary care settings, engaging a
relevant patient pool with less stringent inclusion
criteria [6].
CRYSTAL (effect of glyCopyrronium or indacateRol
maleate and glYcopyrronium bromide fixed-dose combin-
ation [FDC] on SympToms and heALth status in patients
with moderate COPD) was a 12-week, prospective, multi-
centre, open-label study carried out in clinical practice
settings to evaluate the impact of a direct switch to GLY
or IND/GLY from previous standard-of-care treatments
on lung function and dyspnoea in symptomatic patients
with moderate COPD.
In this manuscript, we focus on the fully recruited
and adequately powered groups directly switched to
IND/GLY; the results of the GLY groups are described
in the Additional file 1: Section S6, Tables S1, S2, S3
and S4 and Figures S5 and S6.
Methods
Study design and patients
CRYSTAL was a prospective, multi-centre, 12-week,
randomised, open-label, pragmatic study, designed to
evaluate the effectiveness and safety of GLY or IND/GLY
after a direct switch from previous treatments in clinical
settings in patients with moderate COPD. The study
comprised a 30-day safety follow-up period, conducted
from June 2014 to April 2016 at 560 sites across 23
countries in Europe, in both hospital and primary care
settings (Fig. 1 and Additional file 1: Figure S1).
CRYSTAL included patients aged ≥40 years with a
clinical diagnosis of COPD [7], current or ex-smokers
with a smoking history of ≥10 pack-years, a modified
Medical Research Council (mMRC) score ≥1, a moderate
post-bronchodilator airflow limitation (forced expiratory
volume in 1 s [FEV1] ≥50% and <80% predicted and FEV1/
forced vital capacity (FVC) ratio <0.7) and patients who
have been on a stable dose of baseline treatment with any
short-acting β2-agonists (SABA) and/or short-acting
muscarinic antagonists (SAMA) or LABA or LAMA or
LABA + ICS in free or FDCs for at least 3 months before
screening. Patients who had a body mass index (BMI)
>40 kg/m2, active/clinical history of asthma, narrow-
angle glaucoma, urinary retention or severe renal impair-
ment, malignancy of any organ system in the past 5 years,
any cardiac disorders (myocardial infarction, arrhythmia,
etc.), treatment with non-selective β-blockers, hypersensi-
tivity to any of the investigational drugs or their constitu-
ents used in this study, and ≥2 COPD exacerbations
requiring systemic corticosteroids and/or antibiotics or
Fig. 1 CRYSTAL study design (groups switched to IND/GLY). *Free or fixed-dose combination. †Randomisation ratio (switched: baseline treatments) = 3:1
by stratifying background medications. All comparisons were for superiority of the switched treatment. COPD, chronic obstructive pulmonary disease;
ICS, inhaled corticosteroids; IND/GLY, indacaterol/glycopyrronium; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC,
modified Medical Research Council; q.d., once daily; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist
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with ≥1 hospitalisation in the previous 12 months were
excluded from the study. The detailed inclusion and
exclusion criteria can be found in the Additional file 1:
Sections S1.1 and S1.2.
Patients were randomised (3:1) based on previous
treatments and mMRC scores to either a direct switch
to GLY 50 μg or IND/GLY 110/50 μg q.d. or to remain
on their baseline therapy as active control (Fig. 1 and
Additional file 1: Figure S1). The study was sponsored
by Novartis and was performed according to the Declar-
ation of Helsinki. All patients provided written informed
consent (ClinicalTrials.gov number: NCT01985334).
During the course of the study, recruitment of patients
switched to GLY was significantly lower than expected.
Therefore, recruitment in these groups was stopped at the
time of completion of randomisation in the groups of pa-
tients switched to IND/GLY. Analysis was performed in all
study groups, but GLY groups were underpowered. In this
manuscript, we focus on the fully recruited and adequately
powered groups directly switched to IND/GLY; the results
of GLY groups are described in the Additional file 1: Sec-
tion S6, Tables S1, S2, S3 and S4 and Figures S5 and S6.
Study objectives
The co-primary endpoints of the study were (i) superiority
of IND/GLY against LABA or LAMA and LABA + ICS;
(ii) superiority of GLY versus SABA and/or SAMA and
(iii) non-inferiority of GLY versus LABA or LAMA, in
terms of improvements in trough FEV1 (average of
measurements at 45 and 15 min before dosing) and transi-
tion dyspnoea index (TDI) total score at Week 12. Sec-
ondary objectives included change from baseline in the
total score of COPD assessment test (CAT), clinical
COPD questionnaire (CCQ), use of rescue medications
(number of puffs/day and days without rescue medication
[salbutamol] use) and safety and tolerability of study treat-
ments. TDI, CAT and CCQ assessments were performed
in accordance with standard protocols [8–10]. All patients
recruited in the CRYSTAL study received an electronic
diary (e-diary) for capturing their daily symptoms and
frequency of rescue medication use. Additional details on
the assessment can be found in the Additional file 1 : Sec-
tion S1.4.
Statistical analysis
The intention-to-treat (ITT) population included all ran-
domised patients who received at least one dose of the
study medication, whereas, the per-protocol (PP) popu-
lation comprised all patients in the ITT population with
valid measurements of the primary endpoints without
major protocol deviations (categories of reportable
protocol deviations are listed in the Additional file 1).
Efficacy analyses were performed on both ITT and PP
populations (primary endpoint only for the latter). For
the two co-primary endpoints (trough FEV1 and TDI
after 12 weeks of treatment), a mixed model with treat-
ment as a fixed effect and baseline value as a covariate
was carried out. The primary efficacy endpoints were
analysed for each group separately, based on the number
of patients recruited in each treatment group and their
respective baseline values, without accounting for an over-
all effect in all groups. Hence, evaluation of co-primary
endpoints was done separately for GLY and IND/GLY
groups. In addition, the proportion of responders, i.e. pa-
tients reaching a minimal clinically significant change
from baseline (100 mL in trough FEV1; 1 unit in TDI) at
12 weeks, was presented and analysed using the observed
odds ratio (OR) for responders versus non-responders.
Secondary efficacy endpoints (CAT total score, CCQ total
score, number of puffs of rescue medication and patient-
reported symptoms of COPD) were analysed at Week 12
using the Mann–Whitney–Wilcoxon test. The proportion
of CAT and CCQ responders (defined as a significant
change from baseline of −2 and −0.4 units, respect-
ively) were also presented. All safety analyses were
performed on the safety population, consisting of all
patients who received at least one dose of the study
treatment.
Results
Demographics and baseline characteristics
Of the 4389 patients randomised in the study, 2160 pa-
tients were included in groups that switched to IND/
GLY (baseline treatment with LABA + ICS: n = 1083
[ITT population] and n = 791 [PP population] and base-
line treatment with LABA or LAMA: n = 1077 [ITT
population] and n = 873 [PP population]). Patient dispos-
ition in all groups is presented in the Additional file 1:
Figure S2. Demographic and baseline characteristics of
patients randomised to IND/GLY and comparators are
summarised in Table 1. Differences in mMRC scores and
baseline medication between groups switched to IND/
GLY from LABA or LAMA compared with the patients
switched from LABA + ICS are explained by protocol-
defined inclusion criteria, with most patients who
switched to IND/GLY from baseline LABA or LAMA
having an mMRC score ≥ 2. Demographic information
and baseline characteristics of groups switched to GLY are
presented in the Additional file 1: Table S1.
Impact of a direct switch to IND/GLY on lung function
and dyspnoea (co-primary endpoints)
In the ITT population, IND/GLY provided superior im-
provement in trough FEV1 at Week 12 versus
LABA + ICS (treatment difference [Δ] = +71 mL,
P < 0.0001) and versus LABA or LAMA monotherapies
(Δ = +101 mL, P < 0.0001; Fig. 2a). Similar improve-
ments were observed in the PP population (versus
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LABA + ICS: Δ = +85 mL, P < 0.0001; and versus LABA
or LAMA: Δ = +105 mL, P < 0.0001).
IND/GLY also provided superior improvement in TDI
total score at Week 12 versus LABA + ICS (Δ = 1.10 units,
P < 0.0001) and versus LABA or LAMA monotherapies
(Δ = 1.26 units, P < 0.001; Figure 2B) in the ITT popula-
tion. Similar improvements were observed in the PP
population (versus LABA + ICS: Δ = 1.33 units,
P < 0.0001; and versus LABA or LAMA monotherapies:
Δ = 1.26 units, P < 0.0001).
A significantly higher proportion of patients reached
the minimal clinically important difference (MCID) of
100 mL for trough FEV1 in the IND/GLY groups
compared with LABA + ICS groups (OR: 1.90; 95%
confidence interval [CI]: 1.42 to 2.55) and compared
with LABA or LAMA (OR: 2.53; 95% CI: 1.86 to
Fig. 2 Change from baseline in (a) trough FEV1 and (b) TDI total scores with IND/GLY versus comparators at Week 12 (ITT population).
*P < 0.0001. #Patients had an mMRC score ≥ 2. Data are least squares means (95% CI). Δ, treatment difference; CI, confidence interval; FEV1, forced
expiratory volume in 1 s; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid;
LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; TDI, transition dyspnoea index
Table 1 Demographics and baseline characteristics of patients who switched to IND/GLY (ITT population)
Characteristics LABA + ICS n = 269 IND/GLY n = 811 LABA or LAMAb n = 268 IND/GLYb n = 811
Age, years 64.4 (8.9) 64.6 (8.7) 65.2 (7.6) 65.4 (8.3)
Gender – male, n (%) 164 (61.0%) 528 (65.1%) 176 (65.7%) 537 (66.2%)
Current smoker, n (%) 138 (51.3%) 392 (48.3%) 135 (50.4%) 435 (53.6%)
Post-bronchodilator FEV1, L 1.76 (0.5) 1.80 (0.5) 1.76 (0.4) 1.79 (0.5)
Post-bronchodilator FEV1, % predicted of normal value 63.3 (8.3) 63.7 (8.7) 63.5 (8.2) 63.8 (8.8)
Dyspnoea – mMRC grade, n (%)
0 1 (0.4%) 11 (1.4%) 2 (0.8%) 2 (0.3%)
1 138 (51.3%) 435 (53.6%) 28 (10.4%) 63 (7.8%)
≥ 2 129 (48.0%) 365 (45.0%) 238 (88.8%) 745 (91.9%)
Number of exacerbation in the previous 12 months, n (%)
0 193 (71.8%) 587 (72.4%) 212 (79.1%) 671 (82.7%)
1 72 (26.8%) 220 (27.1%) 56 (20.9%) 136 (16.8%)
≥ 2 4 (1.5%) 4 (0.5%) 0 (0.0%) 4 (0.5%)
Baseline treatments, n (%)a
LAMA (only monotherapy) - 2 (0.2%) 138 (51.3%) 445 (55.1%)
LABA (only monotherapy) - 3 (0.4%) 125 (46.5%) 341 (42.2%)
LABA + ICS (free or fixed-dose combination) 266 (98.9%) 787 (96.7%) - 2 (0.3%)
Othersc 12 (4.4%) 39 (4.8%) 12 (4.5%) 44 (5.5%)
aAt baseline, some of the patients were receiving more than one type of COPD medication
bPatients had an mMRC score ≥ 2
cICS, systemic corticosteroids, methylxanthines, roflumilast etc
Data are presented as mean (standard deviation), unless otherwise stated
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS,
long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council
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3.42; Table 2). A significantly higher proportion of
patients in the IND/GLY groups had reached the
MCID for TDI total score of ≥1 unit compared with
LABA + ICS (OR: 2.61; 95% CI: 1.94 to 3.50) and
LABA or LAMA (OR: 2.85; 95% CI: 2.13 to 3.82;
Table 2). IND/GLY demonstrated consistent improve-
ment in lung function and dyspnoea compared with
LABA or LAMA and LABA + ICS in both ITT and
PP populations during the 12 weeks.
In post-hoc subgroup analyses, IND/GLY provided
consistent improvements in trough FEV1 versus
LABA + ICS or LABA or LAMA in all subgroups of
patients categorised according to age, sex, smoking
status, history of exacerbations in the previous year,
baseline trough FEV1, bronchodilator reversibility,
mMRC score or baseline treatments (Additional file
1: Figure S3A and B). Moreover, IND/GLY provided
consistent improvements in TDI versus LABA + ICS
or LABA or LAMA in all subgroups of patients cate-
gorised according to the same baseline characteristics
(Additional file 1: Figure S4A and B).
Impact of direct switch to IND/GLY on health status and
rescue medication use
Numerical improvements from baseline in the total CAT
score were observed at Week 12 with IND/GLY versus
the comparator treatments; however, these differences
did not reach statistical significance (Table 3). Statisti-
cally significant improvements in the CCQ total scores
from baseline were observed at Week 12 with IND/GLY
versus the comparator treatments. More patients on
IND/GLY reached the MCID of 2-unit improvement in
CAT with IND/GLY versus LABA + ICS (OR: 1.44; 95%
CI: 1.06 to 1.95) and LABA or LAMA monotherapies
(OR: 1.12; 95% CI: 0.83 to 1.50; Table 3).
Patients switched to IND/GLY presented lower rescue
medication use (puffs/day) and more days without
rescue medication use compared with patients who con-
tinued on LABA + ICS or LABA or LAMA (Table 3).
Safety
The safety profile of GLY and IND/GLY was comparable
to that of comparators (Table 4 and Additional file 1:
Table 2 Effects of direct switch to IND/GLY from baseline treatments on trough FEV1 and TDI total scores: proportion of patients
achieving MCID (ITT population)
LABA + ICS n = 269 IND/GLY n = 811 LABA OR LAMAa n = 268 IND/GLYa n = 811
Patients achieved MCID in trough FEV1
(≥100 mL difference from baseline)
90 (33.4%) 379 (46.7%) 74 (27.6%) 388 (47.8%)
Trough FEV1 responders (improvement ≥100 mL;
OR [95% CI])
1.90 (1.42 to 2.55) 2.53 (1.86 to 3.42)
Patients achieved MCID in TDI total scores
(≥1-unit difference from baseline)
91 (33.8%) 427 (52.7%) 95 (35.5%) 466 (57.5%)
TDI responders (improvement ≥1 unit; OR [95% CI]) 2.61 (1.94 to 3.50) 2.85 (2.13 to 3.82)
aPatients had an mMRC score ≥ 2
Data are presented as n (%), unless otherwise stated.CI, confidence interval; FEV1, forced expiratory volume in 1 s; IND/GLY, indacaterol/glycopyrronium; ITT,
intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; MCID, minimal clinically important differ-
ence; OR, odds ratio; TDI, transition dyspnoea index
Table 3 Effects of a direct switch to IND/GLY from baseline treatments on CAT, CCQ and rescue medication use (ITT population)
LABA + ICS n = 269 IND/GLY n = 811 LABA or LAMAa n = 268 IND/GLYa n = 811
Total CAT score, change from baseline at Week 12 −0.4 (4.8) −1.4 (5.4) −0.9 (5.0) −1.9 (5.3)
Patients who achieved MCID in total CAT score
(≥2 units difference from baseline), n (%)
89 (33.1%) 311 (38.4%) 112 (41.8%) 351 (43.3%)
CAT responders (decrease ≥2 units; OR [95% CI]) 1.44 (1.06 to 1.95) 1.12 (0.83 to 1.50)
Total CCQ score, change from baseline at Week 12 −0.1 (0.7) −0.2 (0.8)* −0.1 (0.8) −0.3 (0.8)***
Patients who achieved MCID in the total CCQ score
(≥0.4 units difference from baseline), n (%)
64 (23.8%) 243 (30.0%) 74 (27.6%) 293 (36.1%)
CCQ responders (decrease ≥0.4 units; OR [95% CI]) 1.53 (1.10 to 2.12) 1.58 (1.16 to 2.17)
Number of puffs of rescue medication over 12 weeks 1.6 (1.7) 1.1 (1.4)**** 1.4 (1.4) 1.1 (1.3)***
Percentage of days without rescue medication use
over 12 weeks
41.7 (42.9) 49.9 (43.4)** 38.8 (42.6) 46.7 (42.6)**
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
aPatients had an mMRC score ≥ 2
Data are presented as mean (stadard deviation), unless otherwise stated
CAT, COPD assessment test; CCQ, clinical COPD questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IND/GLY, indacaterol/
glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; MCID, minimal clinic-
ally important difference; mMRC, modified Medical Research Council; OR, odds ratio
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Table S5). There were numerical differences between
IND/GLY and the continued baseline treatments. How-
ever, there were no differences in severe or fatal adverse
events between the various treatment groups, and no new
safety signals related to any treatment were identified in
this study. Four deaths, two in each group, those switched
to IND/GLY from LABA or LAMA and those who
remained on LABA or LAMA, were reported during the
study, and none were considered to be treatment related.
Discussion
In the randomised, open-label CRYSTAL study in patients
with moderate COPD, a direct switch to IND/GLY re-
sulted in significant improvements in lung function and
dyspnoea compared with continuation of LABA or
LAMA monotherapies and LABA + ICS combinations.
Patients on IND/GLY also achieved improvements in
health status and presented reduced rescue medication
use, with a safety profile similar to that reported in RCTs.
This is, to the best of our knowledge, the first study to
evaluate the effectiveness of a step-up strategy from sin-
gle long-acting bronchodilators to a dual bronchodilator.
This is in accordance with the recent Global Initiative
for Chronic Obstructive Lung Disease (GOLD) 2017
strategy document that suggests escalation to dual
bronchodilation in patients who have high level of symp-
toms and low risk of developing exacerbations (GOLD
group B) and remain symptomatic on a LABA or LAMA
[1]. Existing evidence supports the de-escalation of appro-
priate stable COPD patients from triple therapy
(LABA + LAMA + ICS) to dual bronchodilation [11, 12],
but data supporting treatment escalation are lacking. The
CRYSTAL study supports the GOLD step-up recommen-
dation from a single bronchodilator regimen to IND/GLY
in symptomatic patients [1].
Although the efficacy and safety of IND/GLY has been
demonstrated in well-designed explanatory trials, real-
world evidence is currently missing. In pragmatic trials
conducted in clinical practice settings, outcome mea-
sures are typically clinically-relevant assessments that
may support clinicians to decide between a new
intervention and previously available treatments [5]. The
use of less stringent inclusion and exclusion criteria and
direct switching between treatments without a washout
period mimics the way treatment changes occur in clinical
practice [5]. The CRYSTAL study implemented a direct
switch from various available treatments in symptomatic
patients with moderate COPD, without a washout period.
In the CRYSTAL study, patients were switched from a
particular treatment to IND/GLY and patients continuing
baseline therapy (LABA + ICS or LABA or LAMA) served
as the control group. The study was conducted in 23
European countries and included approximately 50%
non–hospital-based investigators (office-based pulmonol-
ogists and general practitioners), thus representing a wide
range of clinical practice settings.
The efficacy and safety results of IND/GLY in this
study were consistent with previous explanatory trials of
the IGNITE programme, consisting of 11 trials con-
ducted in >11,000 patients with moderate-to-very severe
COPD [3, 4, 13]. In the 26-week ILLUMINATE study,
IND/GLY demonstrated superior improvements in the
trough FEV1 of 103 mL [3], whereas in the 1-year
FLAME study, the Δ was 62 mL compared with LABA/
ICS [4]. Similarly, in the 26-week SHINE study, IND/
GLY showed greater improvements in lung function in
trough FEV1, with a Δ versus its monocomponents IND
and GLY of 70 mL and 90 mL, respectively and 80 mL
versus the open-label tiotropium [14]. IND/GLY also
demonstrated a significant improvement in TDI versus
salmeterol-fluticasone in the ILLUMINATE study
(Δ = 0.76 units) and versus LABA or LAMA (e.g. with a
Δ of 0.51 units versus open-label tiotropium in the
SHINE study [3] and 0.49 units versus blinded
tiotropium in the 6-week BLAZE study [15]). Studies of
other available LABA/LAMA FDCs (e.g. aclidinium/
formoterol and umeclidinium/vilanterol) have reported
significant improvements in dyspnoea in comparison
with baseline or placebo, but in some of these studies,
non-significant differences were also observed when
compared with active comparators such as LAMA or
LABA/ICS [16–19].
Table 4 Treatment-emergent adverse events and serious adverse events during the study period (safety set)
LABA + ICS n = 269 IND/GLY n = 816 LABA or LAMAa n = 269 IND/GLYa n = 814
Any adverse event 56 (20.8%) 235 (28.8%) 58 (21.6%) 221 (27.2%)
Any serious adverse event 6 (2.2%) 22 (2.7%) 10 (3.7%) 34 (4.2%)
Any suspected drug-related adverse event 2 (0.7%) 52 (6.4%) 2 (0.7%) 34 (4.2%)
Any suspected drug-related serious adverse event 1 (0.4%) 1 (0.1%) 0 (0.0%) 0 (0.0%)
Any adverse event leading to treatment withdrawal 2 (0.7%) 22 (2.7%) 3 (1.1%) 26 (3.2%)
Any adverse event with a fatal outcome (death) 0 (0.0%) 0 (0.0%) 2 (0.7%) 2 (0.3%)
aPatients had an mMRC score ≥ 2
Data are presented as number of incidences (%)
IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist;
mMRC, modified Medical Research Council
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In the CRYSTAL study, IND/GLY showed greater
improvements in TDI total score versus the comparators
than those observed in previous RCTs. The open-label
comparison of a new and effective drug versus previous
treatments may have resulted in a more pronounced ef-
fect on TDI total score. The inclusion of objective end-
points has been strongly recommended in open-label
trials as they are less prone to bias [20], and therefore
FEV1 was a pre-specified co-primary endpoint in this
study. The improvements in dyspnoea (TDI) and lung
function (trough FEV1) in CRYSTAL were concurrent
and the magnitude of the effect on lung function was
similar to that shown in RCTs. Based on the above facts,
we believe that the greater improvement in TDI total
score, although higher than that observed in RCTs, is
not a chance finding.
A higher numerical reduction in CAT total score with
IND/GLY versus both LABA + ICS and LABA or
LAMA monotherapy was observed that did not reach
statistical significance. In contrast, there was a statisti-
cally significant improvement in the CCQ total score
versus both comparators. A potential explanation for
this discrepancy is that different scores have different
sensitivities in the response to treatment. Moreover,
CAT is a health status tool that was developed to help
patients and their clinicians assess and quantify the
symptoms and impacts of COPD [21] and has been
shown so far to be responsive to changes in health status
following exacerbations and to pulmonary rehabilitation
[22]. Further studies are needed to evaluate the respon-
siveness of different health status tools to pharmacother-
apy options.
The overall incidence of adverse events was similar in
the investigational and comparator treatment groups,
with a slightly higher percentage in IND/GLY groups.
This difference may be attributed to a potential report-
ing bias of adverse events against the newly initiated
treatment (IND/GLY) compared with previous treat-
ments that have already been well tolerated by the pa-
tients. In open-label trials, there is a risk of increased
adverse event reporting, both from patients who may
research the ‘new’ drug and may be influenced in their
reporting behaviour, as well as from the investigators
who may be more susceptible to report adverse events
related to the new drug [23]. Importantly, the overall
incidence of severe and fatal adverse events was similar
in the IND/GLY and comparator treatments.
Improvements in lung function, symptoms, quality of
life and exercise tolerance represent major needs for
patients with COPD. Although we did not evaluate the
exercise capacity of patients in the CRYSTAL study, the
improvement in breathlessness and health status may
resonate in improvement of exercise tolerance in certain
patients [24]. Long-acting bronchodilators also act as
lung deflators, which may lead to the improvement in
static and dynamic hyperinflation [25]. IND/GLY has
demonstrated significant improvements in inspiratory
capacity, dyspnoea, exercise capacity and other patient-
reported outcomes in RCTs [3, 4, 24, 26, 27], and the
consistent results of the CRYSTAL study support that
these beneficial effects may be experienced also in routine
clinical practice.
The CRYSTAL study was appropriately designed to
complement previous RCTs by providing information on
a direct switch to IND/GLY under routine clinical prac-
tice conditions, but, as other open-label studies, may
have certain limitations. Firstly, some of the non-
frequently exacerbating patients with moderate COPD
recruited in the CRYSTAL study were appropriately
treated with a single long-acting bronchodilator, whereas
most of the patients on LABA + ICS were
inappropriately treated according to the GOLD recom-
mendations [28], as it happens often in clinical practice.
Importantly, the CRYSTAL study results show that even
in these mildly symptomatic patients, the switch from a
mono-bronchodilator regimen (with or without ICS) to
a dual bronchodilator (IND/GLY) significantly improved
their lung function, breathlessness and overall quality of
life. Secondly, the duration of the study was only
12 weeks, and this short time frame does not allow for a
clear understanding of the long-term effectiveness of
IND/GLY and its potential effects on exacerbations and
long-term safety. Nevertheless, the consistency of the
CRYSTAL study results with those of previous RCTs in-
dicates that the effectiveness of IND/GLY in clinical set-
tings is likely to be similar to the efficacy observed in
RCTs. Moreover, the direct switch from a LABA + ICS
regimen may raise a question on carry-over effect of
pre-treatments; however, given the short half-life of ICS,
a period of 12 weeks is long enough to make any carry-
over effects of ICS treatment unlikely. The third limita-
tion is the fact that it was an open-label study with a po-
tential reporting bias regarding patient-reported
outcomes, e.g. measures of dyspnoea and health-related
quality of life. However, in order to avoid a selection bias
in this open-label study setting, patients were rando-
mised at baseline. Finally, the short study duration does
not allow for appropriate evaluation of exacerbation pre-
vention in this setting. The results of the CRYSTAL
study provide reassurance on the efficacy and safety of
dual bronchodilation compared with mono-
bronchodilators or LABA + ICS combinations.
Conclusion
In the CRYSTAL study, a direct switch to IND/GLY
demonstrated significant improvements in lung function
and dyspnoea after 12 weeks of treatment in symptom-
atic patients with moderate COPD compared to the
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continuation of previous treatment with LABA or
LAMA or LABA + ICS.
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